Treatment Outcomes and Prognostic Factors for Patients with Soft-tissue Sarcoma at Maharat Nakhon Ratchasima Hospital

  • Khrongkamol Sihaban
Keywords: soft-tissue sarcoma treatment prognosis


  This 10-year retrospective study aimed to evaluate the outcomes and prognosticfactors for patients with soft-tissue sarcoma at Maharat Nakhon Ratchasima Hospital. An analysis of 236 patients who underwent treatment was conducted with 117 males and 119 females having a mean age of 52.7 years (standard deviation 16.5 years). Of these, 88.6 percent presented with a painless mass, and most tumors (52.1%) were located at the extremities. In terms of stage, 87.3 percent of the patients showed localized cancer.
The tumors were over 5 size in 80.5% of cases. The three most common pathologies were leiomyosarcoma (16.1%), liposarcoma (14.4%), and dermatofibrosarcoma
protuberans (14.4%). The treatments for soft-tissue sarcoma comprised surgery (91.1%), radiation (30.1%), and chemotherapy (12.3%). The overall 3-year and 5-yearsurvival rates were 68.9% and 60.7%, respectively. For localized cancer, the 3-year and 5-year survival rates were 73% and 64.2%, respectively. The metastatic cancer patients had a 3-year survival rate of 39%. The factors that significantly affect survival outcomes were age greater than 60 years (OR=2.42, P<0.01), tumor size larger than 5 cm. (OR=2.34, P=0.02), early stage of the cancer (OR=3.60, P=0.02), and surgical treatment (OR=0.35, P=0.02). These results reaffirm the importance of patient status, early detection of cancer, and curative surgery, which are improving survival outcomes.


Download data is not yet available.


1.Russell WO, Cohen J, Enzinger F, Hajdu SI, Heise H, Martin RG, et al. Aclinical and pathological staging system for soft tissue sarcomas. Cancer 1977;40:1562-70

2.Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.

3.Goldblum JR, Folpe AL, Weiss SW, Enzinger FM, Weiss SW. Enzinger and Weiss’s Soft Tissue Tumors. 6th ed. Philadelphia,PA: Saunders/Elsevier;2014.

4.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30.

5.Stiller CA, Trama A, Serraino D, Rossi S, Navarro C, Chirlaque MD, et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer 2013;49:684-95.

6.Pisters PWT, Weiss M, Maki R, Raut CP. Soft tissue sarcomas. In: Pazdur R, Wagman LD, Camphausen K, Hoskins WJ, editors. Cancer Management: A Multidisciplinary Approach, Medical, Surgical and Radiation Oncology. 13th ed. UBM Medica LLC; 2010.

7.Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchère D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue
sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001;91:1914-26.

8.Singer S, Maki R, O' Sullivan B. Soft tissue sarcoma. In: De Vita VT, Lawrence TS, Rosenberg SA, editors. De Vita, Hellman, and Rosenbergs Cancer: Principles & Practice of
Oncology. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011.1533-77.

9.Amin MB, Edge SB. AJCC Cancer Staging Manual. 8th ed. Switzerland: Springer; 2017.

10.Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, et al. Prognostic factors for patients with localized soft tissue sarcoma treated with conservation
surgery and radiation therapy: an analysis of 1225 patients. Cancer 2003;97:2530-43.

11.Italiano A, Le Cesne A, Mendiboure J, Blay JY, Piperno-Neumann S, Chevreau C, et al. Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of
soft tissue sarcoma patients in the competing risks setting. Cancer 2014;120:3361-9.

12.Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996;14:1679-89.

13.Eilber FC, Rosen G, Nelson SD, Selch M, Dorey F, Eckardt J, et al. High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect
on morbidity and mortality. Ann Surg 2003;237:218-26.

14.Gronchi A, Casali PG, Mariani L, Miceli R, Fiore M, Lo Vullo S, et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities:
a series of patients treated at a single institution. J Clin Oncol 2005;23:96-104.

15.Trovik CS, Bauer HC, Alvegård TA, Anderson H, Blomqvist C, Berlin O, et al. Surgical margins, local recurrence and metastasis in soft tissue
sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. Eur J Cancer 2000;36:710-6.

16.Tanabe KK, Pollock RE, Ellis LM, Murphy A, Sherman N, Romsdahl MM. Influence of surgical margins on outcome in patients with preoperatively
irradiated extremity soft tissue sarcomas Cancer 1994;73:1652-9.

17.Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol 2018;29 (Suppl 4) :iv51-iv67

18.Clasby R, Tilling K, Smith MA, Fletcher CD. Variable management of soft tissue sarcoma: regional audit with implycations for specialist care. Br J Surg 1997;84:1692-6.

19.Kiatisevi P, Asavamongkolkul A, Phimolsarnti R, Waikakul S, Benjaras samerote S. The outcomes and prognostic factors of patients with soft-tissue sarcoma. J Med Assoc Thai 2006;

20.ทะเบียนมะเร็งระดับโรงพยาบาล พ.ศ. 2561 สถาบันมะเร็งแห่งชาติ กรมการแพทย์ กระทรวงสาธารณสุข หน้า 27-8

21.Springer S, Tap WD, Crago AM, O'Sullivan B. Soft tissue sarcoma. In: De Vita VT, Lawrence TS, Rosenberg SA. De Vita, Hellman, and Rosenbergs Cancer:
Principles & Practice of Oncology. 10th ed. Philadelphia: Wolters Kluwer; 2015.p.1384-474.

22.Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002;20:791-6.

23.SEER.SEER Cancer Statistics Review, 1975-2016 [internet]. Bethesda: National Cancer Institute ; 2019 [updated 2020 Apr 9; cited 2020 Apr 30]. Available from:https://seer.can /csr/1975_2016/.

24.Gronchi A, Lo Vullo S, Colombo C, Collini P, Stacchiotti S, Mariani L, et al. Extremity soft tissue sarcoma in a series of patients treated at a single institution:
local control directly impacts survival. Ann Surg 2010;251:506-11.

25.Antman KH. Adjuvant therapy of sarcomas of soft tissue. Semin Oncol 1997;24:556-60.

26.Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localized resectable soft tissue sarcoma in adults. Sarcoma Meta-analysis
Collaboration (SMAC). Cochrane Database Syst Rev 2000(2):Cd001419.

27.Sarcoma Meta-analysis Collaboration. Adju-vant chemotherapy for localized resectable soft tissue sarcoma of adults: meta-analysis of individual data.
Sarcoma Meta-analysis Collaboration. Lancet 1997; 350(9092):1647-54.

28.Frustaci S, De Paoli A, Bidoli E, La Mura N, Berretta M, Buonadonna A, et al. Ifosfamide in the adjuvant therapy of soft tissue
sarcomas. Oncol 2003;65 (Suppl 2):80-4.

29.Petrioli R, Coratti A, Correale P, D'Aniello C, Grimaldi L, Tanzini G, et al. Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue
sarcoma. Am J Clin Oncol 2002; 25:468-73.

30.Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide,
and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 2012;13:1045-54.

31.Le Cesne A, Ouali M, Leahy MG, Santoro A, Hoekstra HJ, Hohenberger P, et al. Doxorubicin based adjuvant chemotherapy in soft tissue
sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol 2014;25:2425-32.
Original Articles